Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535295 | 0.84 | NOTUM (0.61) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL6697763 | 0.82 | EPHX1 (0.69) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL2535693 | 0.82 | EPHX1 (0.61) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL22803696 | 0.82 | NPC1 (0.67) | MAOBNPC1RAB9AMAPTEPHX1 | |
| SCHEMBL31668688 | 0.80 | MAOA (0.66) | MAOBNPC1RAB9AMAPTEPHX1 | |
| SCHEMBL4347943 | 0.80 | NPC1 (0.69) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL12969365 | 0.80 | ROCK2 (0.70) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL9705403 | 0.80 | MAOB (0.55) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL9261957 | 0.79 | EGFR (0.60) | MAOBNPC1RAB9AMAPTNOTUM | |
| SCHEMBL9260337 | 0.79 | EPHX1 (0.76) | MAOBNPC1RAB9AMAPTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4249475-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2023-09-27 | — | — | EP | disclosed |
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022108377-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | (주) 메디프론디비티 | 2022-05-27 | — | — | WO | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAOB 1218/4885NPC1 2032/4885RAB9A 892/4885 |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | MAOB 873/4885NPC1 3307/4885RAB9A 2825/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAOB 1218/4885NPC1 2032/4885RAB9A 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.